Abstract

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma
Arnaud Jaccard ... Diane Damotte
Blood | VOL. 138
Arnaud Jaccard, et. al.Arnaud Jaccard ... Diane Damotte
05 Nov 2021
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Theresa Davey ... Esther Drill
Blood | VOL. 134
Theresa Davey, et. al.Theresa Davey ... Esther Drill
13 Nov 2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
...
Blood | VOL. 134
, et. al. ...
13 Nov 2019
Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation
Benjamin L Lampson ...
Blood | VOL. 138
Benjamin L Lampson, et. al.Benjamin L Lampson ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Luisa Corrêa De Araujo Koury ... Eduardo M Rego
Blood | VOL. -
Luisa Corrêa De Araujo Koury, et. al.Luisa Corrêa De Araujo Koury ... Eduardo M Rego
28 May 2024
Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle.
Carys S Johnson ... Elisa Laurenti
Blood | VOL. -
Carys S Johnson, et. al.Carys S Johnson ... Elisa Laurenti
28 May 2024
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
Berit J Brinkmann ... Sascha Dietrich
Blood | VOL. -
Berit J Brinkmann, et. al.Berit J Brinkmann ... Sascha Dietrich
28 May 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Matthew J Frigault ... Marcela V Maus
Blood | VOL. -
Matthew J Frigault, et. al.Matthew J Frigault ... Marcela V Maus
23 May 2024
View more papers